Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Longitude Prize

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

Lilly launches global Alzheimer’s campaign with Julianne Moore

The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health

- PMLiVE

GSK to explore link between Shingrix and dementia risk in new UK research collaboration

More than 55 million people worldwide are currently living with the neurodegenerative disease

- PMLiVE

UK drug repurposing study identifies several potential dementia treatments

An estimated 982,000 people in the UK are currently living with the neurodegenerative disease

- PMLiVE

Eli Lilly shares positive results for modified titration of Alzheimer’s drug donanemab

The neurodegenerative disorder accounts for up to 75% of the 982,000 dementia cases in the UK

- PMLiVE

Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn

Frontotemporal dementia accounts for less than one in 30 cases of the neurodegenerative disorder

- PMLiVE

Lancet Commission report identifies two new modifiable dementia risk factors

The new risk factors identified are untreated vision loss and high low-density lipoprotein

- PMLiVE

Study reveals GSK’s new recombinant shingles vaccine could reduce dementia risk

Shingrix reduced dementia diagnoses by 17% compared to Merck & Co’s Zostavax after six years

- PMLiVE

NHS figures reveal record number of people in England being diagnosed with dementia

Around a third of people living with dementia in England have not received a diagnosis

- PMLiVE

AI tool better predicts progress of Alzheimer’s versus current clinical tests

The most common form of dementia accounts for up to 80% of all cases

- PMLiVE

Alzheimer’s Research UK awards Scottish universities £100,000 for dementia research

The neurological condition affects more than 944,000 people in the UK

- PMLiVE

Takeda gains exclusive option for AC Immune’s Alzheimer’s drug candidate in deal worth over $2.1bn

The agreement includes an option to licence global rights to the anti-amyloid beta immunotherapy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links